Status:
COMPLETED
Spironolactone Versus Spironolactone Plus Furosemide (SVSSF)
Lead Sponsor:
University of Padova
Conditions:
Cirrhosis
Ascites
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The question whether the sequential diuretic therapy, that means using an antialdosteronic drug at first and adding a loop diuretic in nonresponders, is better than the combination of the two diuretic...
Eligibility Criteria
Inclusion
- Grade 2 ascites
- Serum creatinine less than 1.2 mtg/dl
- Serum sodium \> 130 mmol/l
- Serum potassium within 3.5 and 4.5 mmol/l
- At least five days after the withdrawal of diuretics
- A 90 mmol/day Na diet.
Exclusion
- Any therapeutic paracentesis for ascites before inclusion
- Cardiac or respiratory disease
- Gastrointestinal bleeding, hepatic encephalopathy, bacterial infections in the last 4 weeks before inclusion.
- The use of NSAIDs or other nephrotoxic drugs in the last 4 weeks before inclusion.
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2008
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00741663
Start Date
April 1 2005
End Date
September 1 2008
Last Update
September 25 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Padova, Dept. of Clinical and Experimental Medicine
Padua, Italy, 35100